Skip to main content
. 2021 Feb 18;12:615802. doi: 10.3389/fneur.2021.615802

Figure 6.

Figure 6

TG6-10-1 treatment does not ameliorate or alter eFSE-evoked epileptogenesis. (A) Schematic of experimental design. TG6-10-1 treatment failed to alter the latency to onset of spike series post eFSE (B), the total number of aberrant EEG spikes recorded in the first 7 days (C), the first 60 days (D) nor the duration of each spike series (E).